These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 35243106)

  • 1. Immunological significance of alternative splicing prognostic signatures for bladder cancer.
    Li X; Yang L; Huang W; Jia B; Lai Y
    Heliyon; 2022 Feb; 8(2):e08994. PubMed ID: 35243106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
    Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma.
    Wan Z; Wang Y; Li C; Zheng D
    Open Life Sci; 2023; 18(1):20220682. PubMed ID: 37588995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative splicing event associated with immunological features in bladder cancer.
    Yu X; Luo B; Lin J; Zhu Y
    Front Oncol; 2022; 12():966088. PubMed ID: 36686818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
    Chen J; Liao Y; Li R; Luo M; Wu G; Tan R; Xiao Z
    Technol Cancer Res Treat; 2022; 21():15330338221090093. PubMed ID: 35509211
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer.
    Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M
    Cancer Manag Res; 2022; 14():67-88. PubMed ID: 35023971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Exploration of Tumor Microenvironment Modulation Based on the ESTIMATE Algorithm in Bladder Urothelial Carcinoma Microenvironment.
    Chen J; Lv B; Zhan Y; Zhu K; Zhang R; Chen B; Jin Y; Li Y; Zheng J; Lin C
    Front Oncol; 2022; 12():724261. PubMed ID: 35237505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comprehensive and systematic identification of BLCA-specific SF-regulated, survival-related AS events.
    Liu Z; Liu X; Liu F; Zhao H; Zhang Y; Wang Y; Ma Y; Wang F; Zhang W; Petinrin OO; Yao Z; Liang J; He Q; Feng D; Wang L; Wong KC
    Gene; 2022 Aug; 835():146657. PubMed ID: 35710083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of cancer- associated fibroblasts related risk signature based on single-cell RNA-seq and bulk RNA-seq data in bladder urothelial carcinoma.
    Liu Y; Jian J; Zhang Y; Wang L; Liu X; Chen Z
    Front Oncol; 2023; 13():1170893. PubMed ID: 37124542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-Wide Analyses of Prognostic and Therapeutic Alternative Splicing Signatures in Bladder Urothelial Carcinoma.
    Fan Z; Zhang Z; Piao C; Liu Z; Wang Z; Kong C
    Front Oncol; 2021; 11():626858. PubMed ID: 33842332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer.
    Zhang L; Li L; Zhan Y; Wang J; Zhu Z; Zhang X
    Front Oncol; 2020; 10():542140. PubMed ID: 33552945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of CXCL12 expression reveals the significance of inflammatory fibroblasts in bladder cancer carcinogenesis and progression.
    Du Y; Cao J; Jiang X; Cai X; Wang B; Wang Y; Wang X; Xue B
    Cancer Cell Int; 2021 Nov; 21(1):613. PubMed ID: 34801033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer.
    Zhang LH; Li LQ; Zhan YH; Zhu ZW; Zhang XP
    Front Mol Biosci; 2021; 8():607090. PubMed ID: 33937319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
    Li Y; Xu K; Zhang Y; Mao H; Qiu Q; Yan Z; Liu X; Du Y; Chen Z
    BMC Cancer; 2023 Oct; 23(1):1021. PubMed ID: 37872487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
    Lu H; Wu J; Liang L; Wang X; Cai H
    Front Immunol; 2022; 13():803355. PubMed ID: 35154117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
    Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
    Front Genet; 2021; 12():696912. PubMed ID: 34512722
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma.
    Xu Q; Xu H; Deng R; Li N; Mu R; Qi Z; Shen Y; Wang Z; Wen J; Zhao J; Weng D; Huang W
    Cancer Cell Int; 2021 Apr; 21(1):190. PubMed ID: 33794886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.